GlobeNewswire Clinical StudiesOriginal article
Study Results of Orelabrutinib in Patients with SLE Published in the Journal of Autoimmunity
Data ReadoutpositiveOrelabrutinibPositive
AI Analysis
Summary
Orelabrutinib Phase II trial results for systemic lupus erythematosus were published, demonstrating efficacy and establishing it as the first BTK inhibitor globally with demonstrated efficacy in SLE.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Phase II trial demonstrated efficacy; first BTK inhibitor globally to show efficacy in SLE
Importance:7/10
Sentiment:
0.75
Phase 2SLEBTK inhibitorClinical trialFirst-in-class
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 10, 2026 1:00 PM